Aredia

[Guest guest]

Bisphosphonates: safety and efficacy in the treatment and prevention of

osteoporosis.

Am Fam Physician 2000 May 1;61(9):2731-6 (ISSN: 0002-838X)

Greenspan SL; ST; Bone H; PD; Orwoll ES; Watts NB; Rosen CJ

[Find other articles with these Authors]

University of Pittsburgh School of Medicine, Pennsylvania, USA.

Osteoporosis affects more than 28 million Americans. With the advent of

accessible and affordable diagnostic studies, awareness and recognition of

this disease by patients and clinicians are growing. Osteoporotic fractures

of the spine and hip are costly and associated with significant morbidity

and mortality. Over the past decade, a surge of new antiosteoporotic drugs

have been labeled or are awaiting labeling by the U.S. Food and Drug

Administration. One class of agents used to treat osteoporosis is the

bisphosphonates, which inhibit bone resorption, cause an increase in bone

mineral density and reduce the risk of future fractures caused by aging,

estrogen deficiency and corticosteroid use. Overall, bisphosphonates have

been shown to have a strong safety and tolerability profile.

Major Subject Heading(s) Minor Subject Heading(s) CAS Registry / EC Numbers

Diphosphonates [therapeutic use]

Osteoporosis, Postmenopausal [drug therapy]

Osteoporosis [drug therapy]

Find other articles with similar Subjects.

Alendronate [therapeutic use]

Bone Density [drug effects]

Diphosphonates [pharmacology]

0 (Diphosphonates)

66376-36-1 (Alendronate)

May the wind be always at your back.

mtnbiker@... mountainbiker41@...